BCDA vs. PLUR, BCLI, SABS, CRTX, ZIVO, AIM, EVAX, PMCB, APTO, and SNTI
Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Pluri (PLUR), Brainstorm Cell Therapeutics (BCLI), SAB Biotherapeutics (SABS), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), AIM ImmunoTech (AIM), Evaxion Biotech A/S (EVAX), PharmaCyte Biotech (PMCB), Aptose Biosciences (APTO), and Senti Biosciences (SNTI). These companies are all part of the "medical" sector.
BioCardia (NASDAQ:BCDA) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.
BioCardia has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Pluri has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500.
BioCardia received 11 more outperform votes than Pluri when rated by MarketBeat users.
20.6% of BioCardia shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 20.0% of BioCardia shares are owned by insiders. Comparatively, 10.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
BioCardia has a net margin of -2,208.76% compared to Pluri's net margin of -6,339.59%. Pluri's return on equity of -249.60% beat BioCardia's return on equity.
BioCardia has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
BioCardia currently has a consensus target price of $60.00, indicating a potential upside of 1,512.90%. Given BioCardia's higher possible upside, research analysts clearly believe BioCardia is more favorable than Pluri.
In the previous week, BioCardia and BioCardia both had 1 articles in the media. BioCardia's average media sentiment score of 0.00 equaled Pluri'saverage media sentiment score.
Summary
BioCardia beats Pluri on 9 of the 14 factors compared between the two stocks.
Get BioCardia News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCardia Competitors List
Related Companies and Tools
